Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
Wave Life Sciences initiated the Phase 2a portion of the INLIGHT trial evaluating WVE-007 in obese individuals with high BMI and comorbidities. The progression follows Phase 1 data where a single 240 mg dose reduced visceral fat by 14% and total fat by 5% at six months, while preserving muscle mass and being generally well tolerated.
Key figures
- Placebo ratio
- 3:1
- Phase1 dose mg
- 240
- Follow up months
- 6
- Phase2a bmi range kg m2
- 35-50
- Total fat reduction pct
- -5%
- Visceral fat reduction pct
- -14%
- Waist circumference reduction pct
- -3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.